GI Oncology standard regimen doses remain too high for many real world patients. Retrospective and prospective trials demonstrating benefit of reduced doses or dose escalation are accumulating. #meded #gionc #crcsm #pancsm

Neoadjuvant Single-Cycle Pembrolizumab for Stage I-III MMR-Deficient Colon Cancer: The RESET-C Trial. Read the full article. bit.ly/4dZ0AdP #ColorectalCancer #crcsm

Resharing free access link to the manuscript-shorturl.at/dxpVO

🩸Blood TMB vs tissue TMB in predicting #immunotherapy benefit A study found that patients with high tissue TMB had the best outcomes with IO, even when blood TMB was low. ➡️ High blood TMB alone was less predictive of benefit 🗣️ @SKamath_MD | #ASCO26 ascopost.com/news/june-2026/…

Our Ph3 ALTAIR trial for ctDNA-pos CRC is out now in Nature Medicine! 🔗doi.org/10.1038/s41591-026-0… @NatureMedicine @OncoAlert

Survival outcomes following local excision compared with abdominoperineal resection after chemoradiotherapy for anal squamous cell carcinoma: An NCDB propensity score–matched analysis @surgjournal sciencedirect.com/science/ar…

Older adults with advanced cancer mainly prioritized quality of life, but their treatment preferences were not associated with differences in survival, hospitalization, or adverse effects. ja.ma/3RGvSgH

Daraxonrasib #PancreaticCancer data is a major step, but skin toxicity limits dosing. Timely 4-step algorithm in @OncJournal protects patient QoL & treatment continuity. academic.oup.com/oncolo/adva… #OncoTwitter #PancreaticCancer #Oncology #SupportiveCare

I recorded a video with @Medscape @MedscapeOnc during #ASCO26 on how to critically think about cancer clinical trials. It’s now out. Check it out and apply these principles when you’re evaluating any clinical trial presentation. medscape.com/viewarticle/tox…

Outcomes of Y90-radioembolization as downstaging to liver transplantation HCC and tumoral portal vein thrombosis @HEP_Journal doi.org/10.1097/HEP.00000000… 👉25% sustained downstaging after TARE 👉15% eventually LTx with good outcome 🧐Downstaging is feasible in MVI pts @myESMO @ILCAnews @EASLnews

Narrative review on the 21st Century Cures Act and patient access to oncology test results Thanks to @realbowtiedoc @PauloBergerot @AGovindarajanMD @itsnot_pink @MazieTsangMD @RyanNipp apm.amegroups.org/article/vi…

Clear that interactive in person chalk talks and case based discussions in modern hem onc education are the way to go. Didactic lecture still has a role, but remains overemphasized.

With all the excitement around daraxonrasib, I needed to refresh my RAS inhibitor knowledge, so here we go:

I give the hallmarks of cancer lecture @nyulisom @Perlmutter_CC. KRAS: potential target ➡️ G12C ➡️ now complete revision of my slides! Going to be going on about this for a while to the first year medical students who do not realize how amazing this is yet. 🎉😎🎉

Thrilled and honored on behalf of the whole team, patients, scientific community and more- congratulations and good luck to @BrianWolpin this afternoon @MSKCancerCenter @DanaFarber @RevMedicines - next step is translate to practice!

🚨 The highly anticipated data from RASolute 302 have arrived—and the results are turning heads at #ASCO26. #Daraxonrasib met all primary and key secondary efficacy end points in previously treated PDAC, marking a major milestone for KRAS-targeted therapy in a disease with few effective options. Our coverage includes key perspectives from Brian Wolpin, MD, MPH, and @rachnatshroff on the practice-changing implications of these results!🔬 Read more 📰: onclive.com/view/daraxonrasi… @ASCO #pancsm #oncology

#ASCO26 Benefit for daraxonrasib as expected primarily for G12D/V mutations. Not clear based on based on supplemental if benefit other RAS mutations. Still a major breakthrough and amazing to have contributed to study! Congrats @md_oberstein @Perlmutter_CC co-author on paper!

Neo-CRAG: Ph3 RCT (n=620, gastric/GEJ) - adding neoadj chemoRT to peri-op XELOX improved OS (68 v 38 mo). Limitation=non-FLOT, BUT still relevant IMO b/c: 1) DFS/OS benefit substantial. 2) Improvements in pCR, downstg, LRR supports plausible RT effect on OS. #ASCO26 @OncoAlert

Images from the NET clinic... Working in the NET clinic is often humbling... Tumors do not read textbooks and sometimes, things just do not make sense but yet are happening right in front of you. As I often say, every patient with NET is unique (of course, every patient with cancer regardless of cancer type is unique...) with their own clinical presentation. This patient below has metastatic lung NET, indolent, producing very large amounts of serotonin but with no diarrhea or flushing (serotonin does not cause flushing by the way but does cause diarrhea) so essentially asymptomatic in terms of typical carcinoid syndrome. This patient however has carcinoid heart disease with severe tricuspid and pulmonary valve regurgitation. Interestingly, there is no lower extremity edema but there is pulsatile hepatomegaly (a classic finding), both systolic and diastolic murmur, elevated JVP but not a trace of lower extremity edema. Below you can see evidence of hepatic venous congestion in the venous phase of the CT with what sometimes is called nutmeg liver. That lobular pattern is not seen on the arterial phase or on the recent gadoxetate enhanced delayed MRI imaging. I just thought I should share that carcinoid syndrome can present in very atypical ways without the cardinal symptoms of diarrhea and flushing. In this case, carcinoid heart disease is the only manifestation of the syndrome.

This is exactly what most of the "AI deskilling" and "AI will not replace doctors but rather doctors using AI will replace those who don't" gets wrong. This technology will create new workflows, with their own advantages and risks. It will likely do this faster ...

Practice unfortunately has not changed since we published. Until NCCN endorses dropping the bolus it will persist. Not sure we can get a dataset larger than > 10,000 patient analysis (pubmed.ncbi.nlm.nih.gov/3923…). No one wants to fund a Phase 3 trial front line in this space.